Overview

BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy of formulation BLI1100 to its vehicle in the treatment of moderate-severe acne vulgaris.
Phase:
Phase 2
Details
Lead Sponsor:
Braintree Laboratories